Related Experiment Videos
A novel ubiquitin ligase is deficient in Fanconi anemia
Amom Ruhikanta Meetei1, Johan P de Winter, Annette L Medhurst
1Laboratory of Genetics, National Institute on Aging, National Institutes of Health, 333 Cassell Drive, TRIAD Center Room 3000, Baltimore, Maryland 21224, USA.
Abstract:
Fanconi anemia is a recessively inherited disease characterized by congenital defects, bone marrow failure and cancer susceptibility. Cells from individuals with Fanconi anemia are highly sensitive to DNA-crosslinking drugs, such as mitomycin C (MMC). Fanconi anemia proteins function in a DNA damage response pathway involving breast cancer susceptibility gene products, BRCA1 and BRCA2 (refs. 1,2). A key step in this pathway is monoubiquitination of FANCD2, resulting in the redistribution of FANCD2 to nuclear foci containing BRCA1 (ref. 3). The underlying mechanism is unclear because the five Fanconi anemia proteins known to be required for this ubiquitination have no recognizable ubiquitin ligase motifs. Here we report a new component of a Fanconi anemia protein complex, called PHF9, which possesses E3 ubiquitin ligase activity in vitro and is essential for FANCD2 monoubiquitination in vivo. Because PHF9 is defective in a cell line derived from an individual with Fanconi anemia, we conclude that PHF9 (also called FANCL) represents a novel Fanconi anemia complementation group (FA-L). Our data suggest that PHF9 has a crucial role in the Fanconi anemia pathway as the likely catalytic subunit required for monoubiquitination of FANCD2.
Insights
Fanconi anemia is a rare genetic disorder. Researchers discovered PHF9 (FANCL) as a new protein essential for DNA repair, identifying a novel Fanconi anemia complementation group (FA-L).
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Fanconi anemia (FA) is an inherited disorder causing bone marrow failure and cancer susceptibility.
- FA cells are sensitive to DNA-crosslinking agents like mitomycin C (MMC).
- The FA pathway involves BRCA1/BRCA2 and FANCD2 monoubiquitination, crucial for DNA repair.
Purpose of the Study:
- To elucidate the mechanism of FANCD2 monoubiquitination in the Fanconi anemia pathway.
- To identify novel components of the Fanconi anemia protein complex.
- To characterize the function of a newly identified protein, PHF9, in DNA damage response.
Main Methods:
- Investigated the role of a novel protein, PHF9, within the Fanconi anemia protein complex.
- Assessed the in vitro E3 ubiquitin ligase activity of PHF9.
- Evaluated the necessity of PHF9 for FANCD2 monoubiquitination in vivo.
- Determined the complementation group of PHF9 in a Fanconi anemia cell line.
Main Results:
- Identified PHF9 as a component of the Fanconi anemia protein complex with E3 ubiquitin ligase activity.
- Demonstrated that PHF9 is essential for the monoubiquitination of FANCD2.
- Confirmed that PHF9 deficiency leads to Fanconi anemia-like symptoms, establishing a new complementation group (FA-L).
Conclusions:
- PHF9 (FANCL) is a novel E3 ubiquitin ligase crucial for FANCD2 monoubiquitination in the Fanconi anemia pathway.
- PHF9 represents a new Fanconi anemia complementation group (FA-L), highlighting its critical role in DNA repair.
- The discovery of PHF9 provides new insights into the molecular mechanisms underlying Fanconi anemia and DNA damage response.